The role of somatostatin receptor scintigraphy in predicting treatment response of somatostatin analogues in pancreatic neuroendocrine tumors

#3127

Introduction: Over 50% of pancreatic neuroendocrine tumors (pNETs) are diagnosed with distant metastasis, and somatostatin analogues (SSAs) are considered one of the most popular therapies in metastatic pNETs. However, it is still controversial about the role of somatostatin receptor scintigraphy (SRS) in response to SSA.

Aim(s): To assess the role of SRS in predicting response to SSAs in patients with pNETs.

Materials and methods: A retrospective review of pNET databases of the Pancreatic Oncology Department, Fudan University Shanghai Cancer Center (FUSCC) was performed. All patients were histological confirmed pNET with stage IV. All patients received SSA mono-therapy as first line treatment, such as octreotide LAR or lanreotide Autogel. Hepatic tumor burden (HTB) was scored from 1 to 6 based on liver metastatic number and size. SRS was detected in all patients and kenning score was assessed.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Gao H,

Keywords: pancreatic neuroendocrine tumor, somatostatin analogues, somatostatin receptor scintigraphy, response to treatment,